PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2013 | 3 | 2 | 96-101
Article title

Leczenie niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowania miejscowego lub rozsiewu w kontekście programu lekowego

Content
Title variants
EN
Advanced or metastatic non-small-cell lung cancer treatment – new Polish government regulation
Languages of publication
PL
Abstracts
EN
The article presents the non-small-cell lung cancer current treatment recommendations in consideration of Polish government regulation.
PL
W artykule przedstawiono aktualne zalecenia leczenia niedrobnokomórkowego raka płuca wobec ustaleń aktualnie obowiązującego programu lekowego.
Discipline
Publisher

Journal
Year
Volume
3
Issue
2
Pages
96-101
Physical description
Contributors
  • Klinika Nowotworów Płuca i Klatki Piersiowej Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, coval@coi.waw.pl
  • Katedra i Klinika Pneumonologii, Onkologii i Alergologii, Uniwersytet Medyczny w Lublinie
References
  • Pignon J.P., Tribodet H., Scagliotti G.V. et al.: Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26 (21): 3552-3559.
  • Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352(9124): 257-263.
  • Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al.: Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2012; 30: 172-178.
  • Aupérin A., Le Péchoux C., Rolland E. et al.: Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2010; 28: 2181-2190.
  • Delbaldo C., Michiels S., Syzi N. et al.: Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis. JAMA 2004; 292: 470-484.
  • Boni C., Tiseo M., Boni L. et al.: Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br. J. Cancer 2012; 106: 658-665.
  • Scagliotti G.V., Parikh P., von Pawel J. et al.: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy- Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2008; 21: 3543-3551.
  • Jassem J., Biernat W., Drosik K. et al.: Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma. Pneumonol. Alergol. Pol. 2010; 78(6): 418-431.
  • Petrelli F., Borgonovo K., Cabiddui M. et al.: Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clin. Lung Cancer 2012; 13: 107-114.
  • Hui G., Xin D., Dong W. et al.: Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. Transl. Lung Cancer Res. 2012; 1(2): 129-144.
  • Di Maio M., Chiodini P., Georgoulias V. et al.: Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2009; 27(11): 1836-1843.
  • [online: www.nfz.gov.pl].
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-1812e70d-dd1b-4de3-99de-5890f3c8ea32
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.